LUZHU BIOTECH-B (02480) has released its interim results for the 2026 fiscal year, reporting a net loss of RMB61.62 million, a reduction of 20.6% compared to the same period last year. The company's other income reached RMB6.76 million, marking a 39.4% increase year-on-year, while research and development expenses decreased by 39.7% to RMB30.33 million. Loss per share stood at RMB0.31.

According to the company's announcement, the growth in other income was primarily driven by increased government subsidies and rental income, which was partially offset by lower interest income and reduced sales from immunodiagnostic kit revenue. The decline in R&D expenses is mainly attributed to their correlation with the progress of the company's pipeline, as the majority of pipeline candidates are currently in the preclinical stage, resulting in relatively lower R&D expenditures being recorded.